Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib with or without radiotherapy for BCLC stage C hepatocellular carcinoma
ChiCTR2100046536Phase 3Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Overall survival. Started Jun 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100046536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046536.